Before receiving apabetalone, IPA-predicted TGF-β1 was activated in CKD subjects versus controls (Table 2, z-score 2.01, p < 0.05), consistent with elevated TGF-β1 signaling that accompanies kidney dysfunction [7,9,10]. Here, TGFB1 is linked to chronic kidney disease.